Solid tumors exist in a stressed environment for cell growth. As even the smallest tumors grow they rapidly outstrip new blood vessel formation leading to poor perfusion and hypoxia. Genes induced by hypoxia allow the cancer cell to adapt to the hostile hypoxic environment by switching to anaerobic metabolism, decreasing overall protein synthesis, causing resistance to cell death, producing factors that increase the formation of new blood vessels from the existing vasculature (angiogenesis), and increased metastasis. Tumor cells also frequently develop constitutive upregulation of genes that regulate the hypoxic stress response. These constitutive and adaptive changes make tumors aggressive, resistant to radiation and chemotherapy, and lead to a poor patient prognosis. The hypoxic stress response is a normal physiological process employed in the early stages of embryogenesis but with a limited role in well perfused normal adult tissues. Although the changes result in aggressive, drug-resistant tumors they also provide an Achilles heel for selectively attacking the tumor, because without them the cancer cells will die. Thus, the hypothesis upon which our studies are based is that understanding the pathways that regulate the tumor's response to the stress of hypoxia and the consequences this has for tumor growth, will provide novel targets and the development of agents to selectively treat cancer. The most studied mechanism mediating the cancer cell's response to hypoxia is an increase in the levels of the hypoxia inducible factor-1 (HIF-11) transcription factor. We provide evidence for a new pathway of HIF-11 regulation by the endoplasmic reticulum (ER) unfolded protein response (UPR) that mediates the synthesis of HIF-11 and other stress proteins in hypoxia. We have also identified a novel oxygen independent pathway for HIF-11 degradation mediated by HAF/SART-1 which we have shown to be a novel E3 ubiquitin ligase for HIF-11. We will investigate the mechanisms and regulation of the HAF/SART-1-induced degradation of HIF-11 to provide novel targets for therapeutic intervention. There is ample clinical and experimental evidence for a HIF-11 independent mechanism for maintaining tumor growth in hypoxia. It is known that despite a general inhibition of protein translation during hypoxia the synthesis of HIF-11 and of other stress survival proteins is maintained or even increased. Understanding this mechanism could provide novel drug targets to inhibit the tumor's survival response to hypoxia. The overall goal of our studies is to understand mechanisms that contribute to the maintenance of tumor growth in hypoxia, involving both HIF-11 and other stress proteins that will provide new drug targets and therapeutic strategies for treating cancer.

Public Health Relevance

Hypoxic stress is a feature of all tumors as they grow and outstrip new blood vessel growth, but is not seen in most normal tissues. Tumors have developed mechanisms that allow them to grow in hypoxia, thus, providing an Achilles heel for selectively attacking the tumor. The goal of our studies is to understand these mechanisms in order to provide targets for the development of new types of cancer drugs and strategies for treating cancer

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA098920-11
Application #
8637740
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Forry, Suzanne L
Project Start
2013-05-14
Project End
2015-01-31
Budget Start
2013-05-14
Budget End
2015-01-31
Support Year
11
Fiscal Year
2013
Total Cost
$400,039
Indirect Cost
$194,891
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
020520466
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Nam, S; Chang, H R; Kim, K-T et al. (2014) PATHOME: an algorithm for accurately detecting differentially expressed subpathways. Oncogene 33:4941-51
Spivak-Kroizman, Taly R; Hostetter, Galen; Posner, Richard et al. (2013) Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Cancer Res 73:3235-47
Kim, Yon Hui; Liang, Han; Liu, Xiuping et al. (2012) AMPK* modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. Cancer Res 72:2512-21
Koh, Mei Yee; Lemos Jr, Robert; Liu, Xiuping et al. (2011) The hypoxia-associated factor switches cells from HIF-1?- to HIF-2?-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res 71:4015-27
Kim, Yon Hui; Coon, Amy; Baker, Amanda F et al. (2011) Antitumor agent PX-12 inhibits HIF-1ýý protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase. Cancer Chemother Pharmacol 68:405-13
Schwartz, David L; Bankson, James; Bidaut, Luc et al. (2011) HIF-1-dependent stromal adaptation to ischemia mediates in vivo tumor radiation resistance. Mol Cancer Res 9:259-70
Schwartz, David L; Bankson, James A; Lemos Jr, Robert et al. (2010) Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther 9:2057-67
Jacoby, Jorg J; Erez, Baruch; Korshunova, Maria V et al. (2010) Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. J Thorac Oncol 5:940-9
Koh, Mei Yee; Powis, Garth (2009) HAF : the new player in oxygen-independent HIF-1alpha degradation. Cell Cycle 8:1359-66
Schwartz, David L; Powis, Garth; Thitai-Kumar, Arun et al. (2009) The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 8:947-58

Showing the most recent 10 out of 16 publications